NBPP 2027 Comment Window Slams Shut as Stakeholders Brawl Over Non-Network Plans and Network Adequacy Rollback

The biggest week in marketplace policymaking since the new administration took office ended Friday, March 13, when the comment window on CMS's proposed 2027 Notice of Benefit and Payment Parameters slammed shut at 5 p.m. Eastern. The agency had given stakeholders barely a month — the rule was published February 11 — to respond to a sweeping rewrite of how qualified health plans get certified, how networks are measured, and how millions of Americans select coverage on HealthCare.gov. The result was a comment record so dense and so unusually unified that even the insurance industry's largest trade groups sided with hospitals, patient advocates, and state regulators against several of the proposal's most consequential changes.

That confluence is rare. AHIP and the Blue Cross Blue Shield Association rarely line up beside the Federation of American Hospitals, the American Medical Association, Families USA, the National Health Council, and the Coalition To Preserve Rehabilitation in opposing the same federal rule. They did this week, and the focal point was a new category of marketplace product CMS calls a "non-network plan" — what the Center on Health Insurance Reforms at Georgetown bluntly described as something "worse than a ghost network plan: a no-network plan."

The non-network plan firestorm

Under the proposed rule, beginning in plan year 2027, CMS would allow qualified health plans to skip the contracted-network requirement that has been the foundation of marketplace certification since 2014. Instead of negotiating rates with hospitals and physicians, a non-network plan would simply set a "benefit amount" and certify that "sufficient choice" of providers will accept that amount as payment in full. CMS does not specify how it would measure that sufficiency, does not set a minimum percentage of providers who must agree, and does not require carriers to report which providers actually accept the benefit amount. The Federation of American Hospitals, in a March 13 letter signed by interim president Chip Kahn, warned that the combination of non-network plans and the proposed elimination of standardized plan options would leave "consumers without the assurance and consistency they need to evaluate new plans with increasingly complex benefit designs and cost-sharing structures." AHIP's comment letter hedged: insurers acknowledged the appeal of greater plan-design flexibility but pressed CMS to retain a minimum federal floor for essential community providers, the safety-net clinics that disproportionately serve low-income enrollees.

The American Medical Association weighed in directly with HHS Secretary Robert F. Kennedy Jr. on March 12, the day before the deadline, in a letter laying out concerns about how non-network plans would interact with surprise-billing protections, balance-billing exposure, and the fragile arithmetic that lets exchange enrollees compare plans on a single Healthcare.gov screen. The Legal Action Center, the National Health Council, and Families USA each filed letters on March 13 emphasizing the rule's downstream impact on people with chronic conditions and substance use disorders, populations that depend on continuity of in-network specialists. The Patient Access Network Foundation submitted detailed comments on patient cost-sharing and benefit protections, particularly concerned about new bronze and catastrophic plan cost-sharing flexibility that could shift more out-of-pocket exposure onto patients with high-deductible HSA-eligible plans.

Network adequacy and standardized plans

A second tier of opposition coalesced around two related proposals: scrapping the federal requirement that states establish quantitative time-and-distance standards for network adequacy, and discontinuing standardized plans on the federally facilitated exchange and the state-based exchanges using the federal platform. State regulators argued in their letters that without quantitative standards, state insurance departments would lose the comparative benchmark that lets them tell carriers when a network is geographically thin. The brokers and producers community echoed the concern from a different angle: standardized plans, introduced in the 2023 plan year and expanded in 2024 and 2025, gave consumers a like-for-like comparison across carriers in the same metal level. Eliminating them, brokers warned, would push the marketplace back toward the 2018-era confusion of dozens of incomparable plan designs and dramatically increase the risk of consumers buying coverage that does not match their actual care needs. United States of Care submitted comments on March 13 raising that exact point, calling out the rule's proposed shift of state-flexibility burden onto consumers and brokers without commensurate disclosure requirements.

CMS now has just over six weeks to digest the record and issue a final rule before insurers must lock plan designs and rates for the 2027 plan year. The McDermott+ regulatory team, in its analysis of the proposal, called it "a very full plate" and noted that the compressed timeline gives the agency less runway than usual to respond to comments — a signal that final-rule changes from the proposed version may be modest unless the unified stakeholder pushback prompts CMS to rethink the most far-reaching elements.

Two reports to Congress land the same week

While the NBPP fight dominated payer policy headlines, the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission both delivered their statutorily required March reports to Congress on March 13. MedPAC's fifteen-chapter document recommended that Congress hold hospital inpatient and outpatient payment rates to current law for fiscal year 2027 while distributing an additional $1 billion to safety-net hospitals through a transition to a Medicare safety-net index — an attempt to preserve the financial viability of the country's most vulnerable hospital systems without rewarding broad sector rate inflation. The report also returned to a familiar theme: Medicare Advantage payment is running well above traditional Medicare on a per-beneficiary basis, and MedPAC commissioners want Congress to address the gap before the program's enrollment, now over 32 million seniors, swallows the rest of the trust fund.

MACPAC's parallel report focused on the Medicaid workforce, recommending that Congress require states to publicly report hourly wages paid to home- and community-based services workers to give state Medicaid agencies the data they need to set effective payment rates. The commission also recommended extending the renewal period for HCBS Section 1915 waivers from five years to ten — a quiet but consequential bid to reduce administrative churn for states running long-term services programs that depend on continuous federal authority. Both reports landed against the backdrop of the One Big Beautiful Bill Act's Medicaid changes, which the Congressional Budget Office estimated would reduce federal Medicaid spending by $514 billion and reduce coverage by 13.1 million people through 2035.

Layered on top of those reports, CMS issued a Managed Care Monitoring and Oversight Informational Bulletin on March 11 directing state Medicaid agencies to use prior authorization data from their managed care organizations to identify plans issuing inappropriate denials. The bulletin is the agency's most explicit attempt yet to push states to police MCO behavior on prior authorization without waiting for federal enforcement, and it lands at exactly the moment the carrier-led prior authorization standardization initiative — backed by AHIP, the Blue Cross Blue Shield Association, and roughly 50 plans including all six of the largest publicly traded carriers — is rolling out its first commitments.

Optum Rx deploys AI against pharmacy fraud

The carrier news of the week came from UnitedHealth Group. On March 9, 2026, the company's pharmacy benefit manager Optum Rx announced a broad rollout of artificial intelligence systems designed to identify fraud, waste, and abuse in pharmacy claims. The system flags duplicate prescriptions, unusual refill frequencies, and billing discrepancies, automating a review process that previously required human compliance staff to screen thousands of routine transactions by hand. UnitedHealth said the AI/machine-learning model has already produced a 35 percent reduction in low-value retrospective audits, and that audits using the new advanced pharmacy auditing services recover an average of $2 million per client. The announcement was strategically timed: it dovetails with the CMS CRUSH initiative — the agency's anti-fraud RFI that closes March 30 — and gives UnitedHealth a public counterweight to the Department of Justice criminal probe into Optum Rx physician reimbursement practices that became public in late 2025. The company has spent the past nine months trying to demonstrate that its scale produces program-integrity benefits the federal government cannot easily replicate, and the AI rollout fits that narrative.

The financial subtext is harder to ignore. Caremark replaced Optum Rx as the PBM for the California Public Employees' Retirement System effective January 1, 2026, a high-profile loss that puts pressure on UnitedHealth to demonstrate that the Optum Rx franchise can deliver value through technology rather than scale alone. The AI initiative, paired with the company's earlier announcement that Optum Rx is removing reauthorization requirements from 40 additional drugs in 2026 — including new exemptions for hormone therapy and knee osteoarthritis injectables — is the visible part of that strategy.

The dental and biosimilar footnotes

Two smaller but consequential federal actions landed quietly the same week. The Government Accountability Office published a report on March 9 analyzing 2024 NAIC enrollment data for stand-alone dental and vision insurance and found that market concentration among the three largest carriers in each state ranged from 38 to 98 percent in dental group markets and 41 to 96 percent in vision group markets. Several states essentially have monopoly dental markets — a finding that will likely fuel state-level legislative activity on dental network requirements and pediatric dental cost-sharing. On the same day, the Food and Drug Administration released updated guidance on biosimilar development under the Biologics Price Competition and Innovation Act, intended to ease the regulatory pathway for new biosimilar applicants. With Humira biosimilar uptake having finally surged in 2025 after years of stagnation, the new guidance is an attempt to translate that lesson — that better-formatted regulatory pathways move biosimilar adoption faster than mandates alone — into broader pharmaceutical policy.

What the comment-period drama signals

The center of gravity in marketplace policy this week was the question of whether the federal government should keep refereeing what counts as adequate insurance coverage or step back and let consumers and states sort it out. CMS proposed a substantial step back. Insurers, hospitals, brokers, patient advocates, and state regulators — groups that almost never share a position — all responded with versions of the same answer: not yet, and not without guardrails. The unusual coalition was driven less by ideology than by the practical reality that insurers, providers, and consumers all need a shared definition of "in-network" to function, and removing that scaffold without a replacement would leave every party in the marketplace negotiating bilaterally over what coverage actually means.

The most-cited single statistic in the comment letters captures the stakes. ACA marketplace enrollment reached 23 million in 2026, the Federation of American Hospitals noted in its filing, and average MLRs across participating insurers continue to run above the statutory minimum — meaning the marketplace, by every available financial measure, is functioning. Stakeholders argued that overhauling its foundational architecture during the same policy cycle in which enhanced premium tax credits expire — driving subsidized enrollee premium contributions from an average of $888 in 2025 to $1,904 in 2026 — would compound disruption at exactly the wrong moment. CMS now has six weeks to decide how much of that argument it accepts before the final 2027 NBPP arrives in late April.

For employers and brokers, the immediate import of the week's developments is informational. The 2027 plan year will arrive in October 2026 with a marketplace that may look meaningfully different from today's, depending on how aggressively CMS finalizes the proposed changes. For carriers, the comment record establishes a paper trail of stakeholder objections that will shape both the final rule and the inevitable litigation that follows. And for the 23 million people now covered through ACA marketplaces, the question that the March 13 deadline put squarely on the table is whether 2027's open enrollment window will offer plans with networks they recognize, plans with networks they have to take on faith, or some combination of both.